Related Experiment Video
Updated: Aug 14, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Cardioprotection with adenosine A2 receptor activation at reperfusion
Zhelong Xu1, Robert A Mueller, Sung-Sik Park
1Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. zxu@aims.unc.edu
Abstract:
Pre-ischemic treatment is seldom possible in the clinical setting of acute myocardial infarction. Thus, to successfully save myocardium from infarction, it is required that protective interventions must be effective when applied after ischemia has begun or at the onset of reperfusion. Unfortunately, in spite of a large body of experimental data showing that various interventions are cardioprotective at reperfusion, no specific therapy has yet been established to be clinically applicable. However, recent data from several laboratories have shown that adenosine and its analogues given at reperfusion can markedly protect the heart from ischemia/reperfusion injury. While the experimental data suggest that factors such as adenosine A2 receptor activation, anti-neutrophil effect, attenuation of free radical generation, increased nitric oxide (NO) availability, activation of the PI3-kinase/Akt pathway and ERK, prevention of mitochondrial damage, and anti-apoptotic effects may be involved in the protective effect of adenosine or its analogues, the exact receptor subtype(s), the detailed signaling mechanisms, and interaction between those individual factors are still unknown. A definite answer to these unsolved problems will offer insights into the mechanisms of cardioprotection at reperfusion, and will be critical for developing a successful therapeutic strategy to salvage ischemic myocardium in patients with acute myocardial infarction.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

